These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2744962)

  • 1. L-tryptophan supplementation in Parkinson's disease.
    Sandyk R; Fisher H
    Int J Neurosci; 1989 Apr; 45(3-4):215-9. PubMed ID: 2744962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonergic mechanisms in levodopa-induced "on-off" and sleep disorders in Parkinson's disease.
    Sandyk R
    Int J Neurosci; 1988 Dec; 43(3-4):207-13. PubMed ID: 3243678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with tryptophan of levodopa-associated psychiatric disturbances.
    Beasley BL; Nutt JG; Davenport RW; Chase TN
    Arch Neurol; 1980 Mar; 37(3):155-6. PubMed ID: 7356421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-tryptophan administration in L-dopa-induced hallucinations in elderly Parkinsonian patients.
    Rabey JM; Vardi J; Askenazi JJ; Streifler M
    Gerontology; 1977; 23(6):438-44. PubMed ID: 892450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [L-dopa-induced psychoses and their treatment with L-tryptophan].
    Demling J
    Fortschr Med; 1986 Apr; 104(17):360-2. PubMed ID: 3710403
    [No Abstract]   [Full Text] [Related]  

  • 10. [Motor complications in patients with Parkinson disease treated with levodopa].
    Luquin MR; Obeso JA; Martínez-Lage JM
    Neurologia; 1989; 4(1):4-11. PubMed ID: 2631806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease.
    Cedarbaum JM; Gandy SE; McDowell FH
    Neurology; 1991 May; 41(5):622-9. PubMed ID: 2027475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
    Ko WK; Li Q; Bezard E
    Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does levodopa aggravate Parkinson's disease?
    Blin J; Bonnet AM; Agid Y
    Neurology; 1988 Sep; 38(9):1410-6. PubMed ID: 3412589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mental symptoms in Parkinson's disease during chronic treatment with levodopa.
    Sweet RD; McDowell FH; Feigenson JS; Loranger AW; Goodell H
    Neurology; 1976 Apr; 26(4):305-10. PubMed ID: 944387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor complications associated with chronic levodopa therapy in Parkinson's disease.
    Obeso JA; Grandas F; Vaamonde J; Luquin MR; Artieda J; Lera G; Rodriguez ME; Martinez-Lage JM
    Neurology; 1989 Nov; 39(11 Suppl 2):11-9. PubMed ID: 2685647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-tryptophan in the treatment of levodopa induced psychiatric disorders.
    Miller EM; Nieburg HA
    Dis Nerv Syst; 1974 Jan; 35(1):20-3. PubMed ID: 17894051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin and Parkinson's disease.
    Hesselink JM
    Am J Psychiatry; 1993 May; 150(5):843-4. PubMed ID: 8480847
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of Parkinson's disease with multiple drugs].
    Kuno S
    Nihon Rinsho; 1997 Jan; 55(1):59-64. PubMed ID: 9014424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Motor fluctuations in Parkinson disease: risk factors].
    Grandas F; Luquin MR; Rodríguez M; Vaamonde J; Lera G; Obeso JA
    Neurologia; 1992 May; 7(5):89-93. PubMed ID: 1389297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.